Online inquiry

IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3795MR)

This product GTTS-WQ3795MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets Factor VIIa substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000131.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2155
UniProt ID P08709
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3795MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9187MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ211MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ11792MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MK-3222
GTTS-WQ5126MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAN-04
GTTS-WQ8497MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ948MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-323
GTTS-WQ10479MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ6673MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DMUC5754A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW